Personalised mRNA cancer vaccines tailored to individual tumours are showing early promise in melanoma trials, with larger studies underway.
Individually designed mRNA cancer vaccines, tailored to the mutation profile of each patient's tumour, have shown encouraging results in early-phase melanoma trials.
The approach trains the immune system to recognise neoantigens unique to a patient's cancer, and is being tested alongside existing immunotherapy.
Larger randomised trials are underway. Researchers stress that results so far involve small numbers of patients and short follow-up.
Medical Disclaimer: Treatment information described here reflects research findings and may not apply to your situation. Discuss any treatment decisions with your care team.
